HIV-1 co/super-infection in intravenous drug users

AIDS

Volumn 18, Issue 10, 2004, Pages 1413-1421

  Yerly, Sabine ^a   Jost, Stéphanie ^a   Monnat, Martine ^b   Telenti, Amalio ^c   Cavassini, Matthias ^c   Chave, Jean Philippe ^d   Kaiser, Laurent ^a   Burgisser, Philippe ^c   Perrin, Luc ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b Centre Saint Martin   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d La Source Hospital   (Switzerland)

Author keywords

Co infection; HIV 1; HIV 1 diversity; HIV 1 subtypes; Super infection

Indexed keywords

PROTEINASE; RNA DIRECTED DNA POLYMERASE; VIRUS DNA;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CHRONIC DISEASE; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; EPIDEMIC; FEMALE; FOLLOW UP; GENE SEQUENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INTRAVENOUS DRUG ABUSE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PERSISTENT VIRUS INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEROPREVALENCE; SUPERINFECTION; VIREMIA; VIRUS DETECTION; VIRUS IDENTIFICATION; VIRUS LOAD; VIRUS STRAIN;

ADOLESCENT; ADULT; AGED; FEMALE; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MALE; MIDDLE AGED; PHYLOGENY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SEQUENCE ALIGNMENT; SUBSTANCE ABUSE, INTRAVENOUS; SUPERINFECTION;

EID: 3142680739     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000131330.28762.0c     Document Type: Article

References (26)

1. Kampinga GA, Simonon A, Van de PP, Karita E, Msellati P, Goudsmit J. Primary infections with HIV-1 of women and their offspring in Rwanda: findings of heterogeneity at seroconversion, co-infection, and recombinants of HIV-1 subtypes A and C. Virology 1997, 227:63-76.
2. Ramos A, Hu DJ, Nguyen L, Nguyen L, Phan KO, Vanichseni S, et al. Intersubtype human immunodeficiency virus type 1 super-infection following seroconversion to primary infection in two injection drug users. J Virol 2002, 76:7444-7452.
3. Jost S, Bernard MC, Kaiser L, Yerly S, Hirschel B, Samri A, et al. A patient with HIV-1 superinfection. N Engl J Med 2002, 347;731-736.
4. Altfeld M, Allen TM, Yu XG, Johnston MN, Agrawal D, Korber BT, et al. HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus. Nature 2002, 420:434-439.
5. Koelsch KK, Smith DM, Little SJ, Ignacio CC, Macaranas TR, Brown AJ, et al. Clade B HIV-1 superinfection with wild-type virus after primary infection with drug-resistant clade B virus. AIDS 2003, 17:F11-F16.
6. Korber BG. Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull 2001, 58:19-42.
7. th Conference on Retroviruses and Opportuniste Infections, Seattle, USA, February 2002.
8. Op de Coul EL, Prins M, Cornelissen M, van der Schoot A, Boufassa F, Brettle RP, et al. Using phylogenetic analysis to trace HIV-1 migration among western European injecting drug users seroconverting from 1984 to 1997. AIDS 2001, 15:257-266.
9. Liitsola K, Tashkinova I, Laukkanen T, Korovina G, Smolskaja T, Momot O, et al. HIV-1 genetic subtype A/B recombinant strain causing an explosive epidemic in injecting drug users in Kaliningrad. AIDS 1998, 12:1907-1919.
10. Liitsola K, Ristola M, Holmstrom P, Salminen M, Brummer-Korvenkontio H, Simola S, et al. An outbreak of the circulating recombinant form AECM240 HIV-1 in the Finnish injection drug user population. AIDS 2000, 14:2613-2615.
11. Delgado E, Thomson MM, Villahermosa ML, Sierra M, Ocampo A, Miralles C, et al. Identification of a newly characterized HIV-1 BG intersubtype circulating recombinant form in Galicia, Spain, which exhibits a pseudotype-like virion structure. J Acquir Immune Defic Syndr 2002, 29:536-543.
12. Paraskevis D, Magiorkinis M, Paparizos V, Pavlakis GN, Hatzakis A. Molecular characterization of a recombinant HIV type 1 isolate (A/G/E/?): unidentified regions may be derived from parental subtype E sequences. AIDS Res Hum Retroviruses. 2000, 16:845-855.
13. Yerly S, Vora S, Rizzardi P, Chave JP, Vernazza PL, Flepp M, et al. Acute HIV infection: impact on the spread of HIV and transmission. AIDS 2001, 15:2287-2292.
14. Yerly S, R Quadri R, F Negro F, Barbe KP, Cheseaux JJ, Burgisser P, et al. Nosocomial outbreak of multiple bloodborne viral infections. JID 2001, 184:369-372.
15. Felsenstein J. PHYLIP, Phylogeny Inference Package Version 3.6 (alpha). Seattle: Department of Genetics, University of Washington; 2001.
16. Tyndall MW, Currie S, Spittal P, Li K, Wood E, O'Shaughnessy MV, et al. Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic. AIDS 2003, 17: 887-893.
17. http://hiv-web.lanl.gov/CRFs/CRFs.html., mosaic composition of circulating recombinant forms (CRFs) of HIV-1.
18. Cuevas MT, Ruibal I, Villahermosa ML, Diaz H, Delgado E, Parga EV, et al. High HIV-1 genetic diversity in Cuba. AIDS 2002, 16:1643-1653.
19. Gottlieb GS, Nickle DC, Jensen MA, Wong KG, Grobler J, Li F, et al. Dual HIV-1 infection associated with rapid disease progression. Lancet 2004, 363:619-622.
20. Shibata R, Siemon C, Cho MW, Arthur LO. Nigida SM Jr. Matthews T, et al. Resistance of previously infected chimpanzees to successive challenges with a heterologous intraclade B strain of human immunodeficiency virus type 1. J Virol 1996, 70:4361-4369.
21. Stephens EB, Joag SV, Atkinson B, Sahni M, Li Z, Foresman L, et al. Infected macaques that controlled replication of SIVmac or nonpathogenic SHIV developed sterilizing resistance against pathogenic SHIV (KU-1). Virology 1997, 234:328-339.
22. Stahl-Hennig C, Dittmer U, Nisslein T, Petry H, Jurkiewicz E, Fuchs D, et al. Rapid development of vaccine protection in macaques by live-attenuated simian immunodeficiency virus. J Virol 1996, 77:2969-2981.
23. Barker E, Mackewicz CE, Reyes-Teran G, Sato A, Stranford SA, Fujimura SH, et al. Virological and immunological features of long-term human immunodeficiency virus-infected individuals who have remained asymptomatic compared with those who have progressed to acquired immunodeficiency syndrome. Blood 1998, 92:3105-3114.
24. Fowke KR, Nagelkerke NJ, Kimani J, Simonsen JN, Anzala AO, Bwayo JJ, et al. Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya. Lancet 1996, 348:1347-1351.
25. Hirsch MS, Brun-Vézinet F, D'Aquila RT, Hammer SM, Johnson VA, Kuritzkes DR, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA 2000, 283:2417-2426.
26. Tsui R, Herring BL, Barbour JD, Grant RM, Bacchetti P, Kral A, et al. Human immunodeficiency virus type 1 superinfection was not detected following 215 years of injection drug exposure. J Virol 2004, 78:94-103.